Anaphylaxis and systemic mastocytosis
caused by Solenopsis invicta stings

Mario Geller; Phillip Scheinberg; Mariana C. Castells

doi:10.5935/2526-5393.20230029-en

Clinical and Experimental Communication

Anaphylaxis and systemic mastocytosis caused by Solenopsis invicta stings

Anafilaxia e mastocitose sistêmica ocasionada pela Solenopsis invicta

Mario Geller; Phillip Scheinberg; Mariana C. Castells

http://dx.doi.org/10.5935/2526-5393.20230029-en Arq Asma Alerg Imunol, vol.7, n2, p.219-221, 2023

PDF

Downloads: 0

Abstract

Indolent systemic mastocytosis is a rare disease characterized by an increased number of mast cells in the bone marrow and other tissues, such as the liver, spleen, lymph nodes, and skin. Patients with indolent systemic mastocytosis and high serum tryptase levels are at risk for Hymenoptera venom-induced anaphylaxis. Hymenoptera venom immunotherapy in patients with specific IgE is safe and effective. While some patients can receive ultra-rush venom immunotherapy with minimal side effects, omalizumab effectively protects against anaphylaxis during the build-up phase.

Keywords

Anaphylaxis, indolent systemic mastocytosis, urticaria pigmentosa, imported fire ant, Solenopsis invicta, hymenoptera venom immunotherapy, hereditary alpha-tryptasemia.

Resumo

A mastocitose sistêmica indolente é uma doença rara caracterizada por um número aumentado de mastócitos na medula óssea e em outros tecidos, como fígado, baço, linfonodos e pele. Pacientes com mastocitose sistêmica indolente e altos níveis séricos de triptase correm risco de anafilaxia induzida pelo veneno dos Hymenoptera. A imunoterapia com veneno de himenópteros em pacientes com IgE específica é segura e eficaz. Embora alguns pacientes possam receber imunoterapia com veneno ultrarrápido com efeitos colaterais mínimos, o omalizumabe protegeu efetivamente contra a anafilaxia durante a fase de acúmulo.

Palavras-chave

Anafilaxia, mastocitose sistêmica indolente, urticária pigmentosa, formiga-de-fogo importada, Solenopsis invicta, imunoterapia com veneno de himenópteros, alfa triptasemia hereditária.

References

1. Pardanani A. Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2021;96:508-25.

2. Valent P, Hartmann K, Schwaab, J, Alvarez-Twose I, Brockow K, Bonadonna P, et al. Personalized management strategies in mast cell disorders: ECNM-AIM user’s guide for daily clinical practice. J Allergy Clin Immunol Pract. 2022;10:1999-2012.

3. Valent P, Arock M, Akin C, Metcalfe DD. Recent developments in the field of mast cell disorders: classification, prognostication, and management. J Allergy Clin Immunol Pract. 2022;10:2052-5.

4. González de Olano D, de la Hoz Caballer B, Núñez López R, Sánchez Muñoz L, Cuevas Agustín M, Diéguez MC, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy. 2007;37:1547.

5. González de Olano D, Alvarez-Twose I, Estebán-López MI, Sánchez-Muñoz L, Diaz de Durana MDA, Vega A, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol. 2008;121:519-26.

6. Nath, P, Adams K, Schapira R, Edwards K. Imported fire ant hypersensitivity and mastocytosis: a case series of successful venom immunotherapy. Ann Allergy Asthma Immunol. 2019;122:541-2.

7. Bonadonna P, Zanotti R, Müller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol. 2010;10:347-53.

8. Giannetti M, Silver J, Hufdhi R, Castells, MC. One-day ultrarush desensitization for Hymenoptera venom anaphylaxis in patients with and without mast cell disorders with adjuvant omalizumab. J Allergy Clin Immunol Pract. 2020;8:1431-5.

Submitted date:
10/20/2022

Accepted date:
11/28/2022